GELV, LJPC, BRYN, IMGR, SNSS, CHTL OTCPicks.com Stocks to Watch for Tuesday, December 8th CHTL

Our Stocks to Watch tomorrow include Green Energy Live Inc. (OTCBB: GELV), La Jolla Pharmaceutical Co. (Nasdaq: LJPC), Bryn Resources Inc. (OTC: BRYN), Infinity Medical Group Inc. (OTC: IMGR), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) and ChinaTel Group, Inc. (OTCBB: CHTL).

GREEN ENERGY LIVE INCORPORATED (OTCBB: GELV)

"Up 79.50% on Monday"

Detailed Quote: www.otcpicks.com/quotes/GELV.php 

Green Energy Live Inc. is engaged in developing sustainable biomass-to-energy conversion technology to meet a critical need for the nation's $154 billion livestock industry. The company plans to use its proprietary gasification technology for the development of highly innovative, on-site manure-to-electricity conversion systems to enable livestock farmers and ranchers to convert their animal waste into clean, renewable energy.

GELV News:

December 7 - Green Energy Live Reports on Ongoing Revenue, Distribution Channel, and Customer Contacts Provided by New Subsidiary Business

Green Energy Live Inc. (OTCBB: GELV), a growing clean energy company engaged in developing sustainable biomass-to-energy conversion solutions for the U.S. livestock industry, reports that its acquisition of Comanche Livestock Exchange ("Comanche") has significantly enhanced the company's strategic and financial position. Comanche, which is now a wholly-owned subsidiary of Green Energy Live, provides ongoing revenue, livestock industry expertise, an established distribution channel and contacts with potential customers, improving Green Energy Live's ability to develop and sell manure-to-energy conversion systems.

Green Energy Live subsidiary Comanche is a leanly operated, profitable and growing business that provides ongoing revenue to support company growth and technology development. Comanche has a proven track record of success as a provider of live animal auction and livestock hauling services. In business since 1949, Comanche has an extensive network of livestock industry contacts, existing farm and ranch customers and deep industry expertise. Comanche's management is contracted to stay in place for a minimum of two years. Its established sales and management teams will provide a strategic sales channel for Green Energy Live's manure-to-energy conversion systems.

Green Energy Live plans to use its proprietary gasification technology to develop self contained, small footprint, renewable energy gasification systems to enable livestock operators to convert animal waste into clean energy. The company is focused on innovative biowaste conversion technologies that process methane gas from the manure of cows, pigs, turkeys, chickens and convert it into electricity to supply the farm's power requirements and generate revenue selling surplus power back to local utilities.

Karen Clark, President/CEO of Green Energy Live, commented: "Green Energy Live's acquisition of Comanche Livestock Exchange is a strategic move that strengthens our operational and financial foundations and positions us for sustained growth. Comanche's existing relationships and excellent reputation give us a firm foothold in the industry as well as an established distribution channel for our manure-to-energy conversion technology. We look forward to building on this synergistic relationship for the benefit of shareholders."

LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ: LJPC)

"Up 116.31% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/LJPC.php

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions.

LJPC News:

December 7 - Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company (Nasdaq: LJPC) by Adamis. The transaction was unanimously approved by the boards of directors of both companies and is anticipated to close by the end of the first calendar quarter of 2010 or as soon thereafter as possible. Completion of the transaction is subject to a number of customary closing conditions, including the effectiveness of a registration statement to be filed with the Securities and Exchange Commission relating to the transaction, and approval of Adamis’ and La Jolla’s respective stockholders at stockholder meetings following distribution of a definitive joint proxy statement. After completion of the merger, the combined company expects to trade under the name “Adamis Pharmaceuticals Corporation”.

Adamis’ chief executive officer, Dr. Dennis J. Carlo, will become the chief executive officer of the combined company. Dr. Carlo is a veteran of the pharmaceutical and biotechnology industry. He previously served as CEO of publicly-traded Immune Response Corporation, Vice President of Research and Development and Therapeutic manufacturing of Hybritech Inc. prior to its acquisition by Eli Lilly & Co., and Director of Bacterial Vaccines and Immunology at Merck & Company. Dr. Carlo stated, “This merger is a strategic move to raise additional capital for the purpose of increasing the marketing and sales efforts of our Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) product that we recently launched. In addition, we believe that La Jolla has over ten thousand stockholders and we look forward to them joining the Adamis stockholder base.” Based on its most recent quarterly report filed with the Securities and Exchange Commission, at September 30, 2009, La Jolla had cash and cash equivalents of approximately $5.8 million and liabilities of approximately $1.0 million. La Jolla anticipates that there will be $2.5 million to $3.0 million net cash left in the company at the time of the merger.

Dr. Deirdre Y. Gillespie, La Jolla’s CEO, stated, “The merger of La Jolla and Adamis will create a new specialty pharmaceutical company focused on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. We like the fact that in addition to the prefilled epinephrine syringe, Adamis has a pipeline including products for allergic rhinitis, asthma, and chronic obstructive pulmonary disease. We think Adamis is very unique in that it already has a product on the market and is expected to be profitable in the near-term.”

At the effective time of the merger, each outstanding share of Adamis common stock will be converted into the right to receive one (post-reverse stock split) share of La Jolla common stock. Adamis currently has approximately 46 million outstanding shares of common stock, excluding options, warrants and convertible securities. If the transaction is approved by the stockholders, immediately before the closing of the merger La Jolla will implement a reverse stock split; the precise ratio of the reverse stock split will be determined in accordance with the terms of the merger agreement and is dependent on La Jolla’s net cash at closing (reduced by the amount of La Jolla’s liabilities as of the closing date) and Adamis’ stock price over a period before the closing date subject to a variable discount (which in no event will yield a stock price that is less than $0.20 or greater than $1.50).

The percentage ownership of shares after the merger that will be held by persons who were La Jolla stockholders and Adamis stockholders, respectively, will depend on many factors, including without limitation the reverse stock split ratio for the La Jolla shares, the number of outstanding Adamis shares at the closing date of the merger and other factors. However, Adamis expects that after the closing of the merger, the persons who were La Jolla stockholders before the merger could hold approximately 5% - 30% of the outstanding shares of the combined company. Actual ownership percentages could be higher or lower than these estimates.

The merger agreement contains customary non-solicitation provisions restricting La Jolla’s and Adamis’ rights to negotiate or enter into other acquisition or sale transactions before the closing of the merger, subject to limited exceptions. The merger agreement also contains a number of customary representations, warranties and covenants of both parties. The merger agreement contains certain termination rights for both La Jolla and Adamis upon the occurrence of certain events, and further provides that upon termination of the merger agreement under specified circumstances, either party may be required to pay the other party a termination fee. The merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the U.S. Internal Revenue Code of 1986, as amended.

ABOUT ADAMIS PHARMACEUTICALS

Adamis Pharmaceuticals has two wholly owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs expects to launch a series of niche prescription products in the allergy and respiratory therapeutic area, beginning with the Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) product. Adamis Viral Therapies is focused on the development of patented, proprietary vaccine technology that Adamis believes may have the capability of generating a broad-based immunity for both B Cells (antibody) and T cells (cell mediated immunity). If successful, Adamis’ technology could lead to the development of new vaccines against a multitude of viruses, including chronic hepatitis and all forms of influenza. Shoreline Pacific has acted in an advisory role to Adamis during this transaction.

BRYN RESOURCES INCORPORATED (OTC: BRYN)

"Up 103.64% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/BRYN.php 

BRYN Resources Inc. is focused primarily on exploration and development of mineral resources and is currently arranging for the necessary capital to provide for the expenditures of surface sampling, assay work, IP work and further exploration requirements to define potential drill targets on the 1,980 acres of the Pequop Gold, Golden Eagle, Ace and Ore Claims this summer. The company is also proceeding to acquire additional claims with the JV exploration partner in this high value gold target area on a continuing basis.

BRYN News:

December 7 - Bryn Resources Inc. Comments on Recent Movement on their Stock Price

Bryn Resources Inc. (OTC: BRYN) has been fielding a number of calls from investors in regards to the stock price of the company.

The stock has moved up over 600% this month. However the share price had climbed much higher as little as a week ago.

Bryn Resources can only hypothesize that the stock price has come down from profit taking. Bryn Resources is continuing with their acquisition program. There are several developments which are anticipated.

Management is committed to building value. Shareholders can expect news on drill results on our Cayenne JV, a new JV with a Canadian mining company listed on the CNSX, and the closing of our funding.

Beyond the share reduction, Bryn Resources is also considering a dual listing in Canada as a further way to combat shorts. The share reduction and the dual listing plus the anticipated results should force market makers who short the stock to cover.

INFINITY MEDICAL GROUP INCORPORATED (OTC: IMGR)

"Up 100.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/IMGR.php

Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics.

IMGR News:

March 27 - Infinity Medical Group Inc. Elects to Focus on Corporate Ownership of Its Clinics

Infinity Medical Group Inc. (OTC: IMGR), a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics, is announcing that it is not going forward with the Franchise Strategy proposed by Kerry and Associates and has elected to focus on corporate ownership of its clinics.

Infinity Medical Group Inc. is a specialty healthcare development company whose primary focus is in servicing the cosmetic medical laser and dental implant fields. Infinity Medical Group develops, finances and manages clinics for both medical and dental professionals and aids in their professional development through the emerging fields of medical lasers and dental implants. Infinity differentiates itself by offering "a hands on" approach to systemization, branding, containment, training and development of its group of clinics.

The management at Infinity Medical Group are confident that corporate ownership of our clinics will generate greater revenues and bottom lines for both our group of Dental Implant clinics and our Rejuvena Skin AND Laser Centers.

SUNESIS PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)

"Up 5.26% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php 

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer.

SNSS News:

December 7 - Sunesis Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia at the American Society of Hematology 2009 Annual Meeting

Conference Call Scheduled for December 8 at 2:00 PM EST to Discuss ASH Data Presentations

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced positive data from two Phase 2 clinical trials of the Company's lead drug candidate, voreloxin. The results highlight voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat acute myeloid leukemia (AML). The trial results were presented at the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, LA. The presentations are available on the Sunesis website at www.sunesis.com.

"These results provide us with the efficacy and safety data to move voreloxin forward into pivotal testing," said Steven Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis. "Trial results show that the high rates of remission observed in both trials have translated into durable effects with meaningful preliminary overall survival results. With an anticipated median survival of three and a half to six months on currently available therapies, primary refractory and first relapse AML patients are particularly in desperate need of more effective treatment options. We look forward to discussing these data with the FDA in our End-of-Phase 2 meeting scheduled for the first quarter of 2010."

Phase 1b/2 Clinical Trial of Voreloxin in Combination with Cytarabine in Relapsed/Refractory (Abstract No. 645)

In an oral presentation, Jeffrey Lancet, M.D., Associate Member, Section Chief - Leukemia, Department of Hematologic Malignancies, at the H. Lee Moffitt Cancer Center & Research Institute and a clinical trial investigator, presented data from a Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine, a widely used chemotherapy, in patients with relapsed or refractory AML. The trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered in combination with cytarabine given either as continuous infusion or as a two hour IV infusion. To date, 66 patients have been treated in the expansion Phase 2 populations of the trial, which includes primary refractory and first relapse AML patients. Of these, 64 patients were evaluable for efficacy outcomes.

* Among evaluable first relapse (n=36) and primary refractory patients (n=28), preliminary median overall survival is 7.8 months and the remission rate is 31% (complete remission [CR] 27%, complete remission without full platelet recovery [CRp] 2% and complete remission with incomplete recovery [CRi] 2%). Historical median overall survival data in primary refractory and first relapse patients on currently available chemotherapies range from 3.4 to 5.9 months.

* Voreloxin in combination with either bolus or continuous infusion cytarabine was generally well-tolerated. Infection-related toxicities were the most common Grade 3 or higher non-hematologic adverse events. In addition, Grade 3 or higher oral mucositis was observed.

* All-cause mortality among these patients was 1% at 30 days and 8% at 60 days.

* A recommended pivotal dose-regimen of voreloxin used in combination with cytarabine has been identified.

"Voreloxin has induced remissions in difficult to treat relapsed, primary refractory and relapsed/refractory AML patients," said Dr. Lancet. "Voreloxin used in combination with cytarabine has demonstrated meaningful anti-leukemic activity with an acceptable tolerability profile in these difficult-to-treat patients."

Phase 2 Clinical Trial of Single Agent Voreloxin in Newly Diagnosed Elderly AML (REVEAL-1 Trial) (Abstract No. 1037)

In a poster presentation, investigators presented data from the fully enrolled REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose optimization trial of single agent voreloxin in previously untreated, elderly AML patients who are unlikely to benefit from standard induction chemotherapy. 113 AML patients have been treated in the trial, all of whom had at least one additional adverse risk factor at enrollment, including intermediate or unfavorable cytogenetics in the majority of patients. Median age for patients in the trial was 74 years. The trial includes three dosing schedules: Schedule A, once weekly for three weeks (n=29); Schedule B, once weekly for two weeks (n=35); and Schedule C, on days one and four at either 72 mg/m2 (n=29) or 90 mg/m2 (n=20).

* Median survival was 8.7 months in Schedule A; 5.8 months in Schedule B; and 7.3 months (preliminary) in Schedule C (72 mg/m2 on days one and four).

* Median duration of remission was 10.7 months and one year survival was 38% for Schedule A. For the other schedules, median duration of remission has not been reached and one year survival is too early to evaluate.

* Patients age 75 or older (N=49) with at least 1 additional risk factor at diagnosis, a population identified by the National Comprehensive Cancer Network (2010) AML Guidelines as having poor outcome to standard treatment, experienced a CR rate of 30% and a 30-day all-cause mortality of 5%. Survival in these patients was too early to evaluate.

* Based on trial results, Schedule C has been determined to be the recommended pivotal dose regimen. For Schedule C, response rates (CR and CRp) are 38%; 30- and 60-day all-cause mortality are 7% and 17% with improved tolerability over Schedule A.

"Voreloxin has demonstrated a unique combination of anti-leukemic activity and tolerability, important for patients who are unlikely to benefit from standard induction therapy," said Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, and an investigator in the Phase 2 clinical trial. "Particularly encouraging are the durable response, tolerability and promising survival results in the Schedule C group. I look forward to seeing further data from this trial as it matures, particularly voreloxin's durability and overall survival in Schedule C."

Conference Call and Slide Presentation Information

The company will host a conference call and webcast slide presentation December 8, 2009 at 2:00 PM EST to discuss the Company's new clinical data. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team to review the updated data from the Company's Phase 2 studies of voreloxin. The call can be accessed by dialing 888-726-2443 (U.S. and Canada) or 913-312-1516 (international). To access the live audio webcast and accompanying slide presentation, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website until December 22, 2009.

ABOUT VORELOXIN

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

ABOUT ACUTE MYELOID LEUKEMIA

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

CHINATEL GROUP INCORPORATED (OTCBB: CHTL)

"Up 27.59% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CHTL.php

China Tel Group, Inc. (ChinaTel), through its controlled subsidiaries, provides fixed line telephone, conventional long distance, high speed wireless broadband and telecommunications infrastructure engineering and construction services. ChinaTel is presently building, deploying and operating wireless broadband telecommunications networks in Asia and South America: (I) a 3.5GHz wireless broadband telecommunications network in 29 cities across the People’s Republic of China (PRC) with and for CECT-Chinacomm Communications Co., Ltd., a PRC company that holds a license to build the high speed wireless broadband telecommunications network throughout the PRC; and (II) a 2.5GHz wireless broadband telecommunications network in cities across Peru with and for Perusat, S.A., a Peruvian company that holds a license to build a high speed wireless broadband telecommunications network throughout Peru. ChinaTel’s vision remains clear: (i) to acquire, build, deploy and operate high speed wireless broadband telecommunications networks in key markets throughout the world; (ii) to deliver a new world of wireless communications applications; and (iii) to invest in building long-lasting relationships with customers and partners to lead the broadband industry in customer service and responsiveness. ChinaTel’s strategy is to build leading-edge IP-leveraged solutions advanced by its worldwide infrastructure and leadership in emerging markets.

CHTL News:

November 10 - ChinaTel Group's Infrastructure Growth Expanded by Chinese Government's Selection of CECT - Chinacomm Communications to Provide Surveillance Services Using the Wireless Broadband Network ChinaTel is Deploying for Chinacomm

ChinaTel Group, Inc. (OTCBB: CHTL) (ChinaTel), a leader in high speed wireless broadband and telecommunications infrastructure engineering and construction services, announced that the company's planned infrastructure growth in the People's Republic of China (PRC) has increased significantly. The PRC's Public Security Ministry has chosen CECT - Chinacomm Communications Co., Ltd. (Chinacomm) to provide national security surveillance services using the state of the art wireless broadband network ChinaTel is currently deploying for Chinacomm. ChinaTel, indirectly through its contractual relationships with Chinacomm, has the right to deploy and operate a wireless broadband telecommunications network in 29 PRC cities (Chinacomm Network).

George Alvarez, CEO of ChinaTel, stated, "As we continue to deploy the Chinacomm Network and work with various ministries within the PRC, it has become apparent that our track record of successfully delivering state of the art software and hardware solutions has justified our reputation as a top tier wireless broadband telecommunications company sought after by major segments of the Chinese Government."

Colin Tay, the President of ChinaTel, also commented, "Our relationships in China have enabled us to expand our wireless network to reach segments of the consumer, enterprise and government markets that a few years ago were beyond reach. We are extremely proud of our team and their accomplishments in China in order to become a 'best of class' provider of wireless broadband telecommunication services, and to be recognized by the Chinese Government as a preferred provider of these services."

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org/.

Disclosure: OTCPicks.com has been compensated four thousand dollars by a third party for a previous one-week GELV advertising and promotional program. OTCPicks.com is currently being compensated two thousand five hundred dollars from BlueWave Advisors for GELV advertising and promotion. OTCPicks.com has been compensated ten thousand free trading shares by a third party (Downshire Capital) for BRYN advertising and promotional services.